Wedbush Reiterates Neutral on Ultragenyx Pharmaceutical, Maintains $48 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico has reiterated a Neutral rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and maintained a $48 price target on the stock.
April 17, 2024 | 5:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wedbush analyst Laura Chico reiterates a Neutral rating on Ultragenyx Pharmaceutical with a $48 price target.
The reiteration of a Neutral rating and maintenance of the price target by a reputable analyst suggests no significant short-term price movement is expected. However, the reaffirmation of the price target and rating could stabilize investor confidence in the stock.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100